Commentary: Data monitoring confidentiality and FDA transparency

Clinical Trials

Volumn 12, Issue 1, 2015, Pages 12-14

  London, Alex John ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; BIOLOGICAL FACTOR; NEW DRUG; ROSIGLITAZONE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAREGIVER; CLINICAL TRIAL (TOPIC); COMPETENCE; CONFIDENTIALITY; CONFLICT; COOPERATION; DATA ANALYSIS; DECISION MAKING; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEALTH CARE POLICY; HUMAN; INDEPENDENCE; INTERPERSONAL COMMUNICATION; MEDICAL DEVICE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RESEARCH ETHICS; RISK BENEFIT ANALYSIS; SAFETY; ANONYMIZATION; FEMALE; MALE; ORGANIZATION AND MANAGEMENT; PROCEDURES; STANDARDS;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA ANONYMIZATION; FEMALE; HUMANS; MALE;

EID: 84922362612     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774514561047     Document Type: Note

References (10)

1. London AJ, Kimmelman J and Carlisle B. Rethinking research ethics: the case of postmarketing trials. Science 2012; 336: 544-545.
2. Food and Drug Administration (FDA). Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf
3. Fleming TR. Protecting the confidentiality of interim data: addressing current challenges. Clin Trials 2015; 12: 5-11.
4. Grant AM, Altman DG, Babiker AB, et al.; DAMOCLES Study Group. Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005; 9: 25.
5. National Research Council. The future of drug safety: promoting and protecting the health of the public. Washington, DC: The National Academies Press, 2007.
6. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
7. Ledford H. FDA debates trial-data secrecy. Nature 2014; 511: 519.
8. Lilford RJ, Braunholtz D, Edwards S, et al. Monitoring clinical trials - interim data should be publicly available. BMJ 2001; 323: 441-442.
9. Stephens RJ, Langley RE, Mulvenna P, et al. Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential? Lung Cancer 2014; 85: 116-118.
10. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012; 91: 426-437.